23andMe Admits ‘Mining’ Your DNA Data Is Its Last Hope
By Thomas Germain,
Gizmodo
| 02. 13. 2024
With the business in a tailspin, 23andMe’s CEO assures investors there’s still plenty of money it can make on your genes.
23andMe is in a death spiral. Almost everyone who wants a DNA test already bought one, a nightmare data breach ruined the company’s reputation, and 23andMe’s stock is so close to worthless it might get kicked off the Nasdaq. CEO Anne Wojcicki is on a crisis tour, promising investors the company isn’t going out of business because she has a new plan: 23andMe is going to double down on mining your DNA data and selling it to pharmaceutical companies.
“We now have the ability to mine the dataset for ourselves, as well as to partner with other groups,” Wojcicki said in an interview with Wired. “It’s a real resource that we could apply to a number of different organizations for their own drug discovery.”
That’s been part of the plan since day one, but now it looks like it’s going to happen on a much larger scale. 23andMe has always coerced its customers into giving the company...
Related Articles
By Emily Baumgaertner Nunn, The New York Times | 06.11.2026
When scientists at Columbia University announced they had used a newer technology to precisely edit the genes of human embryos last week, they set the academic community ablaze with debate. Is this good news or bad? How fast will...
By Gina Kolata, The New York Times | 06.11.2026
On my second visit with Nancy Wexler at her Manhattan apartment, she had a gift for me. It was a copy of her newly published memoir, “My Life, My Science: Pursuing a Cure for Huntington’s Disease.”
It had been signed...
By Samuelle Fajutrao Falk , The Conversation | 06.26.2026
When my colleagues and I asked autistic people and parents of autistic children in Sweden how they feel about genetic research in autism, one response stood out: “I hope genetic research finds new ways to help us, not erase us.”...
By Rebecca Simkin, BioNews | 06.29.2026
The US Food and Drug Administration (FDA) is allowing biotech company Regenxbio to reapply for licensing of a gene therapy for Hunter syndrome, in a reversal of its previous decision. Hunter syndrome, or mucopolysaccharidosis type II (MPS II), is a...
